A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: The HOT study

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2753-2760

  DeCensi, A ^a   Bonanni, B ^b   Maisonneuve, P ^b   Serrano, D ^b   Omodei, U ^c   Varricchio, C ^b   Cazzaniga, M ^b   Lazzeroni, M ^b   Rotmensz, N ^b   Santillo, B ^b   Sideri, M ^b   Cassano, E ^b   Belloni, C ^d   Muraca, M ^e   Segnan, N ^f   Masullo, P ^g   Costa, A ^h   Monti, N ⁱ   Vella, A ^j   Bisanti, L ^k   D'Aiuto, G ^l   Veronesi, U ^b   more..

^a GALLIERA HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Gynecology Department Ospadali Civili Brescia   (Italy)

^d VALDUCE HOSPITAL   (Italy)

^e ISPO Firenze   (Italy)

^f CPO Piedmont   (Italy)

^g Vallo della Lucania   (Italy)

^h IRCCS   (Italy)

ⁱ S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^j ASL Roma H   (Italy)

^k Ist Naz Stud/Cura Tumori   (Italy)

^l NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Breast cancer; Chemoprevention; Hormone replacement therapy and low dose; Tamoxifen

Indexed keywords

CYPROTERONE ACETATE; DROSPIRENONE; DYDROGESTERONE; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE; TAMOXIFEN; TIBOLONE; TRIMEGESTONE;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; FRACTURE; HEADACHE; HEART MUSCLE ISCHEMIA; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; NIGHT SWEAT; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; UTERUS CANCER; VAGINA DISCHARGE; VAGINAL DRYNESS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

BREAST CANCER; CHEMOPREVENTION; HORMONE REPLACEMENT THERAPY AND LOW DOSE; TAMOXIFEN;

BREAST NEOPLASMS; CLIMACTERIC; DRUG DOSAGE CALCULATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 84887071898     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt244     Document Type: Article

References (40)

1. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
2. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712.
3. Grodstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
4. Hersh AL, Stefanick MLStafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
5. Fournier A, Kernaleguen C, Panjo H et al. Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause 2011; 18: 219-223.
6. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-1674.
7. Grodstein F, Clarkson TBManson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645-650.
8. Santen RJ, Allred DC, Ardoin SP et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95: s1-s66.
9. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-1477.
10. Beral V, Reeves G, Bull DGreen J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011; 103: 296-305.
11. Fournier A, Mesrine S, Boutron-Ruault MC et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009; 27: 5138-5143.
12. Prentice RL, Chlebowski RT, Stefanick ML et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008; 167: 1207-1216.
13. LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-1314.
14. Veronesi U, Maisonneuve P, Rotmensz N et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727-737.
15. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-824.
16. Lippman ME, Krueger KA, Eckert S et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001; 19: 3111-3116.
17. Khan SA, Rogers MA, Khurana KK et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998; 90: 37-42.
18. Gardner FJ, Konje JC, Abrams KR et al. Endometrial protection from tamoxifenstimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711-1717.
19. Decensi A, Gandini S, Guerrieri-Gonzaga A et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999; 17: 2633-2638.
20. Decensi A, Robertson C, Viale G et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 779-790.
21. Decensi A, Gandini S, Serrano D et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 2007; 25: 4201-4209.
22. Haugan Moi LL, Hauglid FM, Gandini S et al. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res 2010; 16: 2176-2186.
23. Viale G, Giobbie-Hurder A, Regan MM et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-5575.
24. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22: 1736-1747.
25. Nichols HB, Trentham-Dietz A, Hampton JM et al. From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol 2006; 164: 1003-1011.
26. Reeves GK, Beral V, Green J et al. Hormonal therapy for menopause and breastcancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006; 7: 910-918.
27. Anderson GL, Chlebowski RT, Aragaki AK et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476-486.
28. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012; 104: 517-527.
29. Chlebowski RT, Anderson GL, Gass M et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-1692.
30. Decensi A, Maisonneuve P, Rotmensz N et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005; 111: 650-656.
31. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.
32. Gardner FJ, Konje JC, Bell SC et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009; 114: 452-456.
33. Chalas E, Costantino JP, Wickerham DL et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005; 192: 1230-1237.
34. Sestak I, Kealy R, Edwards R et al. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 2006; 24: 3991-3996.
35. Rebbeck TR, Friebel T, Wagner T et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23: 7804-7810.
36. Domchek SM, Friebel T, Neuhausen SL et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? ASCO Annu Meeting Proc 2011; 29: 1501.
37. Decensi A, Bonanni B, Guerrieri-Gonzaga A et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998; 90: 1461-1467.
38. Guerrieri-Gonzaga A, Baglietto L, Johansson H et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10: 967-970.
39. Holmberg L, Iversen OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100: 475-482.
40. von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97: 533-535.